Get the Stockscreener App
9.74
5.85%
-0.605
After Hours:
9.70
-0.04
-0.41%
Absci Corp stock is traded at $9.74, with a volume of 3.19M.
It is down -5.85% in the last 24 hours and up +1.14% over the past month.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
See More
Previous Close:
$10.35
Open:
$10.49
24h Volume:
3.19M
Relative Volume:
0.73
Market Cap:
$1.67B
Revenue:
$1.84M
Net Income/Loss:
$-118.44M
P/E Ratio:
-11.75
EPS:
-0.8291
Net Cash Flow:
$-98.51M
1W Performance:
+0.93%
1M Performance:
+1.14%
6M Performance:
+233.56%
1Y Performance:
+267.55%
1-Day Range:
$9.68
$10.50
1-Week Range:
$9.30
$11.26
52-Week Range:
$2.24
$12.05
Absci Corp Stock (ABSI) Company Profile
Name
Absci Corp
Sector
Industry
Phone
(360) 949-1041
Address
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
9.74 | 1.67B | 1.84M | -118.44M | -98.51M | -0.8291 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-02-25 | Initiated | JP Morgan | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jan-22-25 | Initiated | Needham | Buy |
| Oct-02-24 | Initiated | Guggenheim | Buy |
| Jul-03-24 | Initiated | Morgan Stanley | Overweight |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-04-23 | Initiated | H.C. Wainwright | Buy |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Jul-18-22 | Initiated | Truist | Buy |
| Mar-02-22 | Resumed | Cowen | Market Perform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Nov-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Aug-16-21 | Initiated | BofA Securities | Neutral |
| Aug-16-21 | Initiated | Cowen | Market Perform |
| Aug-16-21 | Initiated | Credit Suisse | Outperform |
| Aug-16-21 | Initiated | Stifel | Hold |
View All
Absci Corp Stock (ABSI) Latest News
ABSCI Corp Agencies, 2024 - OpenSecrets
ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise - Stocktwits
Absci (NASDAQ:ABSI) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Absci Corporation (ABSI) Stock Price, News, Quote & History - Yahoo! Finance Canada
LifeSci Capital Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Absci Corporation Announces Preliminary Details for Phase 2 Storyline? Trial of Ai-Designed Antibody Abs-201? for Endometriosis - marketscreener.com
Absci plans phase 2 trial of ABS-201 for endometriosis in 2027 - Investing.com
Absci Expects to Initiate Mid-Stage Trial of ABS-201 for Endometriosis in Mid-2027 - Yahoo Finance
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis - The Manila Times
Absci (NASDAQ:ABSI) Stock Price Down 8.3%What's Next? - MarketBeat
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know - Eastern Progress
Absci (ABSI) Stock Looks Expensive Against Its Book Value - Yahoo Finance
ABSI News | ABSCI CORP (NASDAQ:ABSI) - ChartMill
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Absci Corporation (ABSI) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Absci (NASDAQ:ABSI) Stock Price Up 12.5%Here's What Happened - MarketBeat
Artificial Intelligence Stocks Worth WatchingSeptember 17th - marketbeat.com
Absci at Morgan Stanley healthcare conference: AI platform meets clinical test - Investing.com
Squarepoint Ops LLC Sells 228,841 Shares of Absci Corporation $ABSI - MarketBeat
Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic - Yahoo Finance
Lifesci Capital Begins Coverage on Absci (NASDAQ:ABSI) - MarketBeat
LifeSci Capital Initiates Absci Corp(ABSI.US) With Buy Rating, Announces Target Price $16 - moomoo.com
BTIG Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $16 - moomoo.com
Absci Corporation Stock (ABSI) Opinions on Investor Conference Participation - Quiver Quantitative
Bank of New York Mellon Corp Buys Shares of 386,832 Absci Corporation $ABSI - MarketBeat
ABSI: Absci Corp Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Absci Corporation $ABSI Shares Bought by Bank of America Corp DE - MarketBeat
Absci (NASDAQ:ABSI) Stock Price Down 4.8%Should You Sell? - MarketBeat
Can Absci’s (ABSI) Low-Frequency Hair Loss Therapy Redefine Its Long-Term Platform Potential? - simplywall.st
Absci Corp CFO Zachariah Jonasson Reports RSU Tax Withholding Share Transaction - Kalkine Media
Absci to Participate in Upcoming Investor Conferences - The Manila Times
Deutsche Bank AG Acquires New Stake in Absci Corporation $ABSI - MarketBeat
Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine - fortune.com
Artia Global Partners LP Acquires Shares of 464,444 Absci Corporation $ABSI - marketbeat.com
Absci (NASDAQ:ABSI) Trading 8.5% HigherWhat's Next? - MarketBeat
Certain Common Stock of Absci Corporation are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
Absci (NASDAQ:ABSI) Shares Gap UpShould You Buy? - MarketBeat
Morgan Stanley Maintains Absci Corp(ABSI.US) With Hold Rating, Raises Target Price to $10 - 富途牛牛
Absci (ABSI) Q2 2026 Earnings Call Transcript - AOL.com
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does. - GlobeNewswire
Ransi Mudalinayake Somaratne Net Worth (2026) - GuruFocus
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - Zacks Investment Research
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma - The Globe and Mail
ABSI Looks 1092.2% Overvalued on GF Value™ - GuruFocus
Absci Corp (ABSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Absci (NASDAQ:ABSI) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Absci (NASDAQ:ABSI) Trading Down 4.4%Here's Why - MarketBeat
Will Absci (NASDAQ:ABSI) Spend Its Cash Wisely? - Moomoo
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Absci Corp. Earnings Call Highlights ABS-201 And Cash - The Globe and Mail
Absci Corp Stock (ABSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):